Everything below concerns peptidase. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-08-24. Where a claim depends on a specific study, the study is described rather than over-claimed.
Published clinical evidence is limited. Most controlled trials were conducted in Russia, enrolled modest numbers of participants, and appeared in Russian-language journals, which restricts independent verification. Reported outcomes include lower anxiety scores, improved attention and memory measures, and changes in fatigue ratings. Reviews written in English note methodological limitations such as small samples and inconsistent endpoints. Whether the compound produces clinically meaningful benefit relative to established anxiolytics is therefore an open question rather than an established finding.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was designed at the Institute of Molecular Genetics of the Russian Academy of Sciences as a structural analogue of tuftsin, a naturally occurring tetrapeptide fragment of the immunoglobulin heavy chain. The added Pro-Gly-Pro tail was intended to slow enzymatic degradation and extend biological activity. In Russia it is registered as an anxiolytic nasal preparation, while regulators elsewhere have not approved it for clinical use.
Proposed mechanisms centre on modulation of the GABAergic system, with reports of altered expression of genes related to GABA-A receptor subunits and changed monoamine turnover. Some studies describe inhibition of enkephalinase, the enzyme that degrades endogenous enkephalins, which may prolong opioid peptide signalling. Effects on brain-derived neurotrophic factor and on cytokine expression have also been reported. These findings come largely from animal models and small human studies, and the precise primary target remains unresolved.
The compound was designed at the Institute of Molecular Genetics of the Russian Academy of Sciences during the 1980s and 1990s. The stated design goal was to retain the immunomodulatory and central nervous system activity attributed to tuftsin while improving resistance to enzymatic breakdown. Adding a proline-rich tail to the short parent peptide was a deliberate strategy, because proline residues restrict the conformations available to many peptidases. The same laboratory produced Semax, an ACTH fragment analog, and both compounds were developed in parallel as short, enzymatically stabilized peptides intended for intranasal use.
Selank is not a naturally occurring peptide and has no known endogenous counterpart in human physiology. Russian-language sources frequently call it TP-7, while English-language sources use the name Selank almost exclusively. Database indexing is uneven, partly because early reports appeared in regional journals that are not widely cataloged. Some summaries describe the material as a tuftsin analog and others as a synthetic heptapeptide; the labels overlap rather than conflict. Citing the primary sequence resolves ambiguity more reliably than the research or trade name alone.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C33H57N11O9 | Free peptide form |
| Molecular mass | About 751.9 Da | Calculated average mass |
| Amino acid sequence | Thr-Lys-Pro-Arg-Pro-Gly-Pro | Single-letter form TKPRPGP |
| Structural basis | Tuftsin analogue | Extended version of a natural tetrapeptide |
| Development origin | Russian Academy of Sciences | Work carried out from the 1980s onward |
Published clinical work is concentrated in Russian-language journals and generally involves small samples without independent replication. Systematic reviews in English note the shortage of randomised, placebo-controlled trials and the difficulty of verifying methods from translated reports. Outcome measures vary between studies, which complicates pooling of results. Interest in the compound as a cognitive or anxiolytic agent therefore rests on a thinner evidence base than the volume of citations suggests. Replication in well-powered trials with preregistered endpoints would be needed before firm conclusions about efficacy can be drawn.
Proposed mechanisms centre on the GABAergic system. Animal and tissue studies report changes in GABA-A receptor expression and reduced activity of GABA transaminase, the enzyme that degrades GABA. Effects on monoamine turnover, including serotonin and dopamine pathways, are also described, and a separate line of work links the peptide to increased expression of brain-derived neurotrophic factor in hippocampal tissue. Most of these findings come from rodent models and cell preparations. How the individual observations combine into a single coherent mode of action is not settled.
Development work on the compound began in the 1980s and 1990s at the Institute of Molecular Genetics in Moscow, within the same research programme that produced the peptide Semax. Early investigators sought a tuftsin derivative with improved resistance to enzymatic breakdown and with activity in the central nervous system after peripheral administration. Most of the primary literature from this period was published in Russian, a factor that still shapes how easily the findings can be checked by outside groups.
Naming for this compound is not fully standardised in English sources. The spelling Selanc appears in some transliterations, and catalogue entries may instead list the peptide sequence itself as the identifier. Reference material sometimes groups it with other short synthetic peptides studied for behavioural effects, which can create confusion when citations are compared. Distinguishing the exact sequence from related tuftsin analogues is therefore a practical first step when reviewing any dataset or specification sheet.
== Divisions == The chain of being hierarchy consists of God at the top, above angels, which like him are entirely spirit, without material bodies, and hence unchangeable. Beneath them are humans, consisting both of spirit and matter; they change and die, and are thus essentially impermanent. Lower are animals and plants. At the bottom are the mineral materials of the earth itself; they consist only of matter. Thus, the higher the being is in the chain, the more attributes it has, including all the attributes of the beings below it. The minerals are, in the medieval mind, a possible exception to the immutability of the material beings in the chain, as alchemy promised to turn lower elements like lead into those higher up the chain, like silver or gold.
Eleven months after reimplantation, a viable intrauterine pregnancy was confirmed, which resulted in the first such live birth – a girl named Tamara. Therapeutic hypothermia, e.g. during heart surgery on a "cold" heart (generated by cold perfusion without any ice formation) allows for much longer operations and improves recovery rates for patients.
==== Education ==== Diabetes management for children requires the integration of the family and health care team to be committed and continuous for promotion of self-management. A health care team may include a pediatric endocrinologist or physician trained in pediatric diabetes, a diabetes specialist nurse, a registered dietitian, a psychologist, a social worker, and child life specialist. The goal of the health care team and child's family is to empower the child to make informed decisions for health‐promoting lifestyle choices.
=== Contestants === 1st - Melanie Bjork-Jensen, Self-taught baker from West Jordan, Utah 2nd/3rd/4th - Alan Arras, Pastry Sous Chef from Orlando, Florida 2nd/3rd/4th - Cory Jones, Bakery Owner from Unadilla, Georgia 2nd/3rd/4th - Oksana Shchelgachova, Pastry Chef and Owner of Pastry Boutique from Highlands, North Carolina 5th - Camille La Caer, Pastry Chef from Buffalo, New York 6th - Jake Hagen, Pastry Chef from Granada Hills, California 7/8th - Gonzuela Bastarache, Home Baker from Moncton, New Brunswick, Canada 7/8th - Megan Carroll, Food Photographer from Minneapolis, Minnesota 9th - Nina Charles, Cake Artist and Bakery Owner from Carencro, Louisiana 10th - Justin Giordano, Cake Artist from New York City, New York
Sources: en.wikipedia.org
In conjunction with the construction of Einstein's first building, New York City built a 1,349-bed, $37.5 million hospital adjacent to the school, now known as the Jacobi Medical Center. Belkin and New York City Mayor Vincent Impellitteri agreed to permit its use as Einstein's teaching hospital. Jacobi is a member of NYC Health + Hospitals, the largest municipal health system in the United States. It serves as both the regional snakebite center and hyperbaric center for the New York tri-state area.
== Fluoroalkenes and fluoroalkynes == Unsaturated fluorocarbons are far more reactive than fluoroalkanes. Although difluoroacetylene is unstable (as is typical for related alkynes, see dichloroacetylene), hexafluoro-2-butyne and related fluorinated alkynes are well known.
=== Initiation === Initiation involves the small subunit of the ribosome binding to the 5' end of mRNA with the help of initiation factors. The ribosome and its associated factors assemble and bind to an mRNA. The first TRNA is attached at the start codon. This process is defined as either cap-dependent, in which the ribosome binds initially at the 5' cap and then travels to the stop codon, or as cap-independent, where the ribosome does not initially bind the 5' cap. The 5' cap is added when the nascent pre-mRNA is about 20 nucleotides long.
== See also == List of benzodiazepines Benzodiazepine dependence Benzodiazepine withdrawal syndrome Long-term effects of benzodiazepines Lofendazam (1,5-benzodiazepine derivative and partial benzodiazepine receptor agonist) Arfendazam (1,5-benzodiazepine derivative and partial benzodiazepine receptor agonist) Triflubazam (1,5-benzodiazepine derivative and partial benzodiazepine receptor agonist) CP-1414S (1,5-benzodiazepine derivative and partial benzodiazepine receptor agonist) Premazepam (pyrrolodiazepine derivative and partial benzodiazepine receptor agonist) Nordazepam (1,4-benzodiazepine derivative and partial benzodiazepine receptor agonist)
In the United States, pembrolizumab is indicated for the treatment of melanoma, non-small-cell lung cancer, malignant pleural mesothelioma, head and neck squamous-cell cancer, classical Hodgkin lymphoma, primary mediastinal large B-cell lymphoma, urothelial cancer, microsatellite instability-high or mismatch repair deficient cancer, microsatellite instability-high or mismatch repair deficient colorectal cancer, gastric cancer, esophageal cancer, cervical cancer, hepatocellular carcinoma, biliary tract cancer, Merkel-cell carcinoma, renal cell carcinoma, endometrial carcinoma, tumor mutational burden-high cancer, cutaneous squamous cell carcinoma, and triple-negative breast cancer. As of 2019, pembrolizumab is used via intravenous infusion to treat inoperable or metastatic melanoma, metastatic non-small cell lung cancer (NSCLC) in certain situations, as a first-line treatment for metastatic bladder cancer in people who cannot receive cisplatin-based chemotherapy and have high levels of PD-L1, as a second-line treatment for head and neck squamous cell carcinoma (HNSCC), after platinum-based chemotherapy, for the treatment of people with refractory classic Hodgkin lymphoma, and recurrent locally advanced or metastatic esophageal squamous cell carcinoma.
Sources: en.wikipedia.org
It is a seven-amino-acid peptide, Thr-Lys-Pro-Arg-Pro-Gly-Pro, produced by chemical synthesis rather than extracted from biological tissue. Its design is based on tuftsin, a natural immunomodulatory tetrapeptide. The C-terminal Pro-Gly-Pro segment is a common stabilising motif in short regulatory peptides.
The core four residues correspond to tuftsin, which occurs naturally as part of immunoglobulin G. The full seven-residue sequence, however, is not a known endogenous peptide. It is a laboratory-designed analogue intended to combine tuftsin-like activity with greater resistance to breakdown.
No single receptor has been confirmed as the primary target. Reports describe involvement of the GABAergic system, interference with enkephalin degradation, and shifts in neurotrophic factor expression. Because these observations come from different models and assays, they have not yet been integrated into one accepted mechanism.
The sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro, written TKPRPGP in one-letter code. It combines the tetrapeptide tuftsin with a carboxyl-terminal Pro-Gly-Pro extension. This full sequence identifies the molecule more precisely than the research name.